Recordati's independent directors face a challenge from shareholder Palliser Capital over whether they support a revised €53-per-share takeover offer from CVC Capital Partners and Groupe Bruxelles Lambert (GBL). The dispute exposes a distinction between welcoming a higher price, assessing its financial fairness and recommending that shareholders accept it.
On 14 October 2026, Palliser asked the independent directors and bidding consortium to clarify their positions by 16 October. Respighi BidCo, the CVC- and GBL-backed bidder, raised its cash offer from €51.29 to €53.00 on 6 October. The revised bid carries maximum cash consideration of €10,521,854,786 if all shares covered by the offer are tendered.
Respighi BidCo regards €53 as full and fair value. Palliser argues that Recordati remains undervalued and has said it will not tender. The uncertainty stems partly from how Recordati's directors evaluated the original price.
On 15 July, six Recordati directors considered the original €51.29 price financially fair, following an assessment that included a fairness opinion from Lazard. The four independent directors, advised separately by Rothschild & Co, concluded that the price was inadequate and the offer as a whole was not fair.
The distinction was formal as well as financial. Under Article 39-bis of Italy's Issuers' Regulation, the independent directors were required to produce a reasoned opinion assessing the offer and its consideration. Their 14 July opinion was separate from the board's wider assessment and expressly stated that it was not a recommendation to accept or reject the offer.
Recordati's board unanimously welcomed the increased price on 7 October. The independent directors acknowledged that €53 now sat within relevant valuation ranges, including Rothschild's discounted cash-flow analysis. However, the announcement referred back to the July opinions and did not explicitly replace their earlier conclusion or recommend tendering.
The relationship between independent expert assessments and board recommendations also features in Finance Gazette's analysis of Brookfield's proposed Reliance Worldwide acquisition, although the applicable takeover procedures differ.
Rothschild's original valuation analysis, included in the takeover document, placed Recordati's discounted cash-flow equity value between €52.01 and €61.25 per share. The revised offer lies near the bottom of that range. A price-to-earnings comparison produced €61.68–€72.66, while comparable transactions indicated €53.76–€58.85. These reflect different valuation methodologies and assumptions rather than alternative bids or binding valuations.
The Rothschild opinion, issued on 14 July, concerned the earlier €51.29 offer and was not an updated assessment of €53. Its calculations depended on projections of future cash flows, discount rates and pharmaceutical products' commercial lives.
Recordati's subsequent first-half results added to the debate. Released on 28 July, they showed Rare Diseases revenue of €603.9 million, up 17.1% as reported and 22.0% like-for-like at constant exchange rates. Isturisa revenue rose 58.0% to €178.8 million.
Palliser has highlighted the division's growth in challenging the revised offer, although historical performance does not by itself establish an appropriate takeover price.
The bid also creates uncertainty over what happens to shares that are not tendered. Respighi BidCo has a 66.67% ownership threshold condition that it may waive. If the offer completes without delisting Recordati, the bidder intends to pursue a subsequent delisting merger, subject to corporate approvals and applicable procedures.
Under the proposed merger structure, certain shareholders who do not tender their shares could exercise withdrawal rights, subject to the applicable conditions. Their exit valuation would use the average closing share price over the six months preceding the relevant meeting notice, potentially producing less than €53. Those retaining shares without exercising withdrawal rights could become shareholders in an unlisted company.
The difference between the amount shareholders receive and the wider economic value of a transaction is examined separately in Finance Gazette's guide to M&A deal values, cash consideration and ownership structures.
There is also a conditional protection for shareholders who accept the offer. If the withdrawal valuation exceeds the offer consideration and the relevant share liquidation occurs within six months of the offer payment date, the bidder would be required to make a corresponding price adjustment to shareholders who tendered. This does not guarantee a higher payment or eliminate the risks associated with the proposed merger.
The offer is scheduled to close on 23 October 2026, with payment scheduled for 2 November. Palliser's request for clarification falls before that deadline, leaving investors to distinguish the board's welcome of the revised price from a fresh independent fairness determination and the conditional consequences of retaining their shares.
